Gilead Sciences (NASDAQ:GILD) CEO Sells $2,783,145.25 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 15,881 shares of the stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $175.25, for a total value of $2,783,145.25. Following the completion of the sale, the chief executive officer owned 566,683 shares of the company’s stock, valued at $99,311,195.75. This trade represents a 2.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, November 2nd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $169.74, for a total value of $2,546,100.00.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total value of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $148.64, for a total value of $2,229,600.00.

Gilead Sciences Price Performance

Shares of GILD opened at $174.48 on Thursday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38. The stock has a 50 day simple moving average of $152.29 and a 200 day simple moving average of $140.52. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $175.65. The firm has a market capitalization of $216.41 billion, a PE ratio of -55.22 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. Gilead Sciences’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the prior year, the business earned $2.47 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post -1.07 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is -103.80%.

Analyst Ratings Changes

A number of equities research analysts recently commented on GILD shares. UBS Group raised their price objective on shares of Gilead Sciences from $175.00 to $195.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Jefferies Financial Group set a $196.00 target price on Gilead Sciences in a report on Wednesday. Royal Bank Of Canada lifted their price target on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research note on Friday, October 30th. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Finally, Truist Financial boosted their price target on Gilead Sciences from $158.00 to $181.00 and gave the company a “buy” rating in a report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.15.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: DZ Bank raised its price target on Gilead to $191 from $167, signaling increased confidence in the stock’s prospects. DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
• Positive Sentiment: Gilead and its Kite subsidiary plan 23 presentations, including seven oral presentations, at the December ASH meeting. The breadth of planned data across the pipeline and portfolio may draw investor attention to potential growth drivers. Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
• Positive Sentiment: BioNTech and Gilead are advancing a global Phase 3 trial combining BioNTech’s pumitamig with Gilead’s cancer drug Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer. The collaboration expands the potential reach of Gilead’s oncology portfolio, though trial results remain to come. BioNTech Enters First Global Phase 3 Trial for New Breast Cancer Combo
• Neutral Sentiment: Gilead’s GS-1206 cancer study continues to advance, but investors are still waiting for early efficacy signals; the update did not provide results that establish the drug’s potential. Gilead’s GS-1206 Cancer Trial Advances as Investors Watch for Early Signals
• Negative Sentiment: Put-option purchases were unusually elevated, which may reflect increased hedging or bearish positioning, though options activity alone does not confirm a negative outlook.
• Negative Sentiment: CEO Daniel O’Day disclosed recent stock sales under a pre-arranged Rule 10b5-1 plan. The planned nature of the sales may limit their significance, but insider selling can still weigh on sentiment.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds have recently made changes to their positions in the business. Bank of Nova Scotia acquired a new stake in Gilead Sciences during the second quarter worth approximately $100,056,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $55,754,000. Groupe la Francaise grew its position in shares of Gilead Sciences by 30.9% in the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after purchasing an additional 11,712 shares during the last quarter. Baird Financial Group Inc. grew its position in shares of Gilead Sciences by 3.6% in the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock valued at $36,929,000 after purchasing an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Gilead Sciences during the second quarter worth approximately $6,251,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.